The Lattice (Official 3DHEALS Podcast)

3DHEALS
  • 5.0 (2)
  • Life Sciences
  • Updated Biweekly

Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 3DHEALS Links: https://linktr.ee/3dheals 🛑 Disclaimer The content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations. While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement. This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings.

  1. Oct 13

    Episode #130 | 3D Print Tiny Things with Adam Steege, Trio Labs

    The more minimally invasive medicine becomes, the smaller and more complex medical devices have to be. While that can mean better care and greater access for patients, it also creates a significant dilemma: how do you manufacture these devices at scale? Adam Steege, founder and CEO of Trio Labs, a Morrisville, North Carolina-based company, develops micron-scale metal parts for medical devices. He invented RIPL, or Resin Infused Powder Lithography, a lithography-based process that prints stainless-steel parts at five-micron resolution with tolerances as fine as 0.0005 inch and Ra32 surface finish, which are specifications normally associated with CNC machining. On The Lattice, Steege explains why Trio sells finished parts rather than 3D printers, how minimally invasive surgery and interventional cardiology push instruments smaller and more complex than machining or metal injection molding can economically produce, and why manufacturability is the third leg, alongside clinical need and design, of every successful device. Ultimately, Trio Labs aims to hit the sweet spot where complex, micron-scale designs lead the next generation of medical devices for patients. 00:00:00 - Welcome And A Parts-First Thesis 00:01:20 - Founder Lessons From A First Startup 00:04:45 - Minimally Invasive Devices Hit Manufacturing Limits 00:09:36 - Why RILP Had To Be Invented 00:11:48 - Selling Parts Instead Of Printers 00:17:06 - RIPL Explained And Where It Wins 00:19:58 - Finding Customers And Building To Production 00:22:50 - Unit Economics Versus CNC And MIM 00:27:19 - Scaling Challenges And The 2027 Goal 00:29:50 - Disclaimer And Closing Show notes: https://3dheals.com/episode-130-3d-print-tiny-things-with-adam-steege-trio-labs/ YouTube: https://youtu.be/8JH1TFZrmeg?si=PCG5O6_js5HRehp8 Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode #130 | 3D Print Tiny Things with Adam Steege, Trio Labs

  2. Oct 1

    Episode #129 | Additive Manufacturing Needs Policy To Reach Patients with Dr. Naomi Nathan

    Healthcare loves innovation right up until the bill shows up. We sit down with Dr. Nayumi Nathan (Naomi), a medical doctor turned public health and health economics leader, to unpack why medical 3D printing and additive manufacturing are often ready before the healthcare system is. If you’ve ever wondered why point-of-care 3D printing can thrive in one hospital and stall in another, the answer is usually not the printer. It is reimbursement, evidence, and policy. We dig into how Mobility Goes Additive (MGA) builds a Europe-wide ecosystem that connects hospitals, MedTech companies, researchers, regulators, and industry partners to move from scattered pilots to real adoption. Naomi explains why the EU is uniquely complex for healthcare market access: health authority is national, so scaling custom medical devices, patient-specific implants, and hospital 3D printing programs means navigating 26+ reimbursement and governance environments. That reality changes how startups and scale-ups should plan timelines, partnerships, and investment needs. The conversation gets concrete on what must happen next: registries, multi-center studies, and credible patient outcome data that can support evidence-based policy and sustainable payment models. We also talk advocacy, political champions, and why additive manufacturing needs “commitment followed by investment,” including scale-up funding, not just startup grants. Along the way, we reality-check bioprinting hype and share what it will take for patients to one day ask for a 3D printed knee like it’s normal. If you care about the future of medical 3D printing in Europe and beyond, listen, subscribe, and share this with someone building in healthcare. After you listen, leave a review and tell us: what is the biggest barrier to adoption where you live? YouTube: coming soon Show notes: coming soon Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode #129 | Additive Manufacturing Needs Policy To Reach Patients with Dr. Naomi Nathan

  3. Sep 27

    Episode #128 | Biotools Can Beat Moonshots with Jim West

    Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded. Show notes YouTube Recording Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode #128 | Biotools Can Beat Moonshots with Jim West

  4. Sep 17

    Episode#127 | Lean Compliance For Medical 3D Printing With Erik Boelen

    We talk with Erik Boelen, founder of Qase3D, about how medical 3D printing went from a regulatory free-for-all to a world where hospital print labs function as medical device manufacturers. We break down MDR, CE marking, ISO 13485, and how to stay compliant with a lean system engineers will actually use.  • The early “no rules” era and why proof of quality becomes unavoidable  • How MDR and CE marking work for standard medical devices  • Why custom-made devices can be CE-exempt yet still heavily regulated  • ISO 13485 as a process-focused QMS and where it helps most  • Building a lean, day-to-day QMS instead of a paperwork vault  • The MDR Portal approach and the value of lawyer-backed interpretation  • Practical triggers for when a growing lab should consider ISO 13485 certification   00:00:00 - Welcome To The Regulatory Reality 00:03:10 - MDR, CE Mark, And ISO 13485 00:06:30 - Making Implants Before Clear Rules 00:08:33 - What Custom Made Really Means 00:10:20 - From Engineer To Quality Builder 00:12:12 - A Lean QMS People Actually Use 00:17:33 - The MDR Portal And Lawyer Support 00:26:45 - Scaling Compliance Without Bureaucracy 00:30:40 - The Future Of Hospital 3D Labs 00:41:05 - How To Contact Erik 00:43:15 - Disclaimer Show notes: https://3dheals.com/episode-127-lean-compliance-for-medical-3d-printing-with-erik-boelen/ YouTube: https://youtu.be/wR7TVN4WGno?si=pvQ-Fl7VJNgNRq7F Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode#127 | Lean Compliance For Medical 3D Printing With Erik Boelen

  5. Sep 14

    Episode#126| Biomaterials Frontier for Medical 3D Printing (Virtual Event Recording)

    The real frontier in medical 3D printing isn't the printer — it's the material. In this 3DHEALS panel, five researchers, founders, and industry leaders map the shift from printing structure to printing function, and from lab-stage novelty toward regulated, investment-grade material systems spanning soft bioresins, bioactive ceramics, and titanium lattices. Fabian Trumper (Arrakis Bio) argues that the best biomaterials are the ones our bodies already make, and explains how his team bio-manufactures True Human Collagen at industrial scale. Prof. Kamal Choudhary (Johns Hopkins) shows why AI is reshaping materials discovery — a "ChatGPT for materials scientists" — and why so much of the field still isn't reproducible. Dr. Andrew Weems (Resilient Medical) shares how a 3D-printed scaffold could finally modernize lumpectomy surgery for breast cancer patients. Ebrahim Yarali (MERLN, Maastricht University) reveals how geometry alone — architected "meta-biomaterials" and 4D printing — can steer stem cells toward bone or cartilage. And Dr. Scott Taylor (Poly-Med) breaks down absorbable polymers that dissolve into the body once healing is done. Moderated by Craig Rosenblum, President of Himed. In this episode: Human vs. synthetic biomaterials — and what cells actually "notice"AI-designed materials and the reproducibility crisisDesigning devices for the surgery we already do4D printing and geometry as a biological signalA live debate: can AI and lab models replace animal testing?Whether you're a researcher, founder, or investor, this is a fast, opinionated tour of where medical materials are heading next. 🎥 Watch the full session and explore more 3DHEALS events: https://3dheals.com/biomaterials-frontier/ 00:00:00 - Welcome And 3D Heals Missions 00:01:58 - Event Setup And Sponsor Context 00:04:08 - Absorbable Polymers And Degradation Design 00:10:07 - Pore Size And Surface Area Effects 00:12:40 - True Human Collagen For Regeneration 00:23:08 - Collagen Q&A On Regulation 00:28:58 - AI Tools For Materials Discovery 00:41:35 - AI Limits Data And Loop Closure 00:50:31 - Lumpectomy Scaffolds And Go To Market 01:01:47 - Academia Versus Startup Mindset 01:10:13 - Geometry Driven Bone Regeneration Scaffolds 01:24:11 - Acoustic Responsive And 4D Biomaterials 01:31:08 - Panel Debate On Animal Testing 01:37:39 - AI Hype Real Impact And Wish List 01:46:51 - Final Takeaways And Closing Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode#126| Biomaterials Frontier for Medical 3D Printing (Virtual Event Recording)

  6. Sep 3

    Episode 125| Inside Tech Transfer At UCLA From Patents To Patients

    A single university discovery can turn into a life-changing therapy, but only if someone can translate the science into a product, a company, and a development plan investors will actually fund. That is why we sat down with Mark from UCLA’s technology transfer and licensing team to demystify what happens after the lab result and before the biotech headline. We talk plainly about what a tech transfer office does, what it can license, and why “intellectual property” now stretches beyond patents into data, materials, and even carefully governed patient datasets. We also zoom out to the policy foundation that made modern university commercialization possible: the Bayh-Dole Act. Mark explains how shifting IP ownership from the federal government to universities changed licensing outcomes and helped build the innovation ecosystem we now associate with US leadership in therapeutics. Along the way, we connect the dots to real UCLA impact, including major prostate cancer drugs and a licensed cure for ADA-SCID, and we unpack the tension founders often feel when a faculty inventor becomes a startup founder negotiating with their own campus. Then we get tactical. We break down why big pharma often waits until risk is reduced, why faculty-led startups become the bridge, and how license strategy changes depending on whether you are building a therapeutic that needs exclusivity or a platform that benefits from nonexclusive access. Mark walks through diligence milestones, annual progress reporting, and the practical reality that most “shelving” is not malicious, it is a startup fighting for survival. If you care about biotech startups, university patents, and the future of the Los Angeles bioscience ecosystem, this conversation is a roadmap. If this helped you see tech transfer differently, subscribe, share the episode with a founder or researcher, and leave a review telling us what part of the university-to-startup journey you want us to unpack next. Show notes: coming soon YouTube: coming soon Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode 125| Inside Tech Transfer At UCLA From Patents To Patients

  7. Aug 20

    Episode#123| Bioprinting In Microgravity with Dr. Michael Roberts ISS/CASIS

    Gravity shapes every lab workflow we take for granted, and it may be the hidden constraint behind some of the hardest problems in regenerative medicine. We sit down with Dr. Michael Roberts, a microecologist who led bioregenerative life support research at NASA’s Kennedy Space Center and now serves as Chief Scientific Officer of the International Space Station National Laboratory, to talk about what microgravity is actually good for and why biomanufacturing in space is no longer just sci-fi. YouTube: Pending Show notes: Pending Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode#123| Bioprinting In Microgravity with Dr. Michael Roberts ISS/CASIS

  8. Aug 7

    Episode #122| The Mini Brain That Learned Pac-Man: NAMs with Dr. Lowry Curley

    A brain organoid that can learn to play Pac-Man sounds like a stunt until you realize what it represents: measurable learning, rewiring, and human-relevant neural function that animal models often fail to predict. We talk with Dr. Lowry Curley, founder of Luna LifeSci and former CEO and co-founder of Axosim (now 28 Bio), about why neuroscience drug development breaks so often and how NAMs are finally giving teams better tools to make safer calls earlier. If you’re building in biotech, investing in drug discovery, or just trying to understand what replaces animal testing next, this conversation gives you a clear map of the technology, the incentives, and the milestones to watch. Subscribe, share this with a colleague, and leave a review with the biggest NAM question you want answered next. Show notes: https://3dheals.com/episode-122-new-approach-methodologies-nams-with-dr-lowry-curley/ YouTube: https://youtu.be/suVxiYZgPVE Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    Episode #122| The Mini Brain That Learned Pac-Man: NAMs with Dr. Lowry Curley
See All (49)

Ratings & Reviews

5
out of 5
2 Ratings

About

Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 3DHEALS Links: https://linktr.ee/3dheals 🛑 Disclaimer The content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations. While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement. This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings.

Information